Pacira BioSciences (PCRX) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.70
- Estimate
- $0.15
- Surprise
- +366.7%
- Revenue (period 2026-09-30)
- $176.7M
- Score today
- 4.9/10
Revenue source: xbrl.
How the report landed
Pacira BioSciences (PCRX) beat the $0.15 estimate with adjusted EPS of $0.70 — a large 366.7% upside surprise.
Coverage in the report window
- Pacira BioSciences Withdraws 2026 Guidance Pending Proposed Merger With Viatris — benzinga, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates PCRX Sell at 4.9/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +366.7% surprise compares with a +87.2% four-quarter average. Next scheduled report: 2027-02-25.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Analyst target reached - limited upside remaining
- Near 52-week high (0.7% away)
- Earnings estimates trending DOWN
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $36.43
- Stop
- $36.31
The stock trades at 39.2× trailing but 10.5× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.
PCRX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.45B
- P/E (fwd)
- 10.5
- P/E (ttm)
- 39.2
- 52-week range
- $18.80–$36.67
- Off 52-week high
- 0.7%
- RSI (14)
- 65
- Volume vs avg
- 0.45×
- Score today
- 4.9/10